Full Stack Software Engineer, Lab Platform (LIMS)

The posting, as insitro wrote it

THE OPPORTUNITY

insitro is a physical AI company dedicated to unlocking causal human biology and accelerating the delivery of better medicines to patients. Our unique Virtual Human™ platform identifies novel, high-impact genetic intervention points, which our TherML™ platform translates into therapeutics—whether small molecules, biologics, or oligos. With multiple programs in metabolic disease and neuroscience advancing toward the clinic, and our first IND submission slated for the second half of this year, we are at a pivotal inflection point.

To enable that mission, we need a software layer that ties together the scientific, automation, and machine learning platforms — that's our Lab Platform: a harness for science, built as an agentic workflow system that lets scientists drive the lab through an agent. Our bar is that everything in the lab should be agentically accessible (any action a scientist can take, an agent can take), agentically legible (agents understand what the data means in insitro's context, not just how to fetch it), and humanly verifiable (a scientist can always check what an agent did and why). This is real robotics, workflow automation, and applied agent tooling — and your users are in the building with you.

You'll work across the stack — front end, backend, and the integrations that reach into instruments, Benchling, and agent runtimes — partnering closely with our machine learning, automation, and biology teams. Based in South San Francisco, this role reports directly to Senior Manager, Software Engineering and offers an in-person hybrid schedule of three days per week. We'll bring you up to speed in the domain of drug development and back your ideas with real trust and mentorship along the way.

RESPONSIBILITIES

Full-Stack Ownership

• Ship Across the Stack: Build the React and TypeScript frontends scientists use every day, the Python services behind them, and integrations that reach instruments, Benchling, and agent runtimes
• Own It End to End: Take a feature from the first conversation with a scientist through the data model and UI to the alert that fires when it breaks
• Do the Normal SWE Things: Write code, review design docs, talk to users, and do code reviews that actually make the codebase better

Agentic Tooling & Experimentation

• Chase User Appreciation: Ship things that make scientists say "OMG, this is amazing, thank you so much."
• Figure Out What's Actually Useful: Test agentic tooling ideas through prototypes, real users, and short iterative loops rather than betting on theory
• Move the Needle: Contribute work that meaningfully advances insitro's mission and the pace of drug development

Cross-Functional Partnership

• Go Watch the Work: Spend time in the lab observing the workflow before you change it
• Partner Broadly: Collaborate closely with machine learning, automation, and biology teams to build tools people actually use
• Keep Humans in the Loop: Design for provenance and

[…]
rovides transport to and from our South San Francisco HQ from locations all around the Bay Area

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

#LI-Hybrid

Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com http://insitro.com, and if in doubt, contact us at info@insitro.com.

About insitro

insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com http://www.insitro.com.